Trial Search Results

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

St. Jude Children's Research Hospital

Stanford Investigator(s):


  • Drug: Adriamycin┬«
  • Drug: Vinblastine
  • Drug: Nitrogen Mustard
  • Drug: Cyclophosphamide
  • Drug: Vincristine
  • Drug: Bleomycin
  • Drug: Etoposide
  • Drug: Prednisone
  • Biological: G-CSF
  • Procedure: Radiotherapy


Phase 2


Inclusion Criteria:

   - Patient is less than or equal to 21 years of age

   - Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma

   - Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal
   involvement (3 or more sites), or bulky mediastinal adenopathy.

Exclusion Criteria:

   - Patients with favorable risk features

   - Patients with unfavorable risk features

   - Patients who have received prior therapy for Hodgkin lymphoma.

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
Not Recruiting